NL-OMON46643CompletedNot Applicable
Home monitoring in Idiopathic Pulmonary Fibrosis; improving use of anti-fibrotic medication and quality of life - IPF online
Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites90 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 90
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •All patients with a diagnosis of IPF according to the ATS 2011 criteria and HRCT/pathology criteria of the Fleischner Society (White paper November 2017), about to start on anti-fibrotic treatment (either nintedanib or pirfenidone) will be invited to participate.
Exclusion Criteria
- •not able to speak, read or write in Dutch,
- •not able to comply with the study protocol according to the judgement of the patient and/or investigator
Investigators
Similar Trials
Completed
Not Applicable
Daily home monitoring in Idiopathic Pulmonary Fibrosis * a pilot study to assess feasibility of a home spirometry and eHealth self-management applicatioidiopathic pulmonary fibrosislung fibrosis10024967NL-OMON45619ongziekten10
Completed
Not Applicable
Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of LifeIdiopathic Pulmonary FibrosisNCT03420235Erasmus Medical Center90
Completed
Unknown
A multi-centre study comparing idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysemaISRCTN28134901Taichung Veterans General Hospital275
Unknown
Phase 2
Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)Idiopathic Pulmonary FibrosisNCT01504334Beijing Kawin Technology Share-Holding Co., Ltd.80
Terminated
Phase 2
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPFPersistent Cough in IPFChronic CoughIPFNCT03864328Respivant Sciences GmbH108